Know a great AI tool or AI news source? Submit it to AiByts
Ars Technica1 min read

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Markers released top-line results today after previously reporting the trial succeeded.

By Beth MoleArs Technica
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Read the full story

Originally published by Ars Technica on Oct 22, 2026.

Read on Ars Technica(opens in a new tab)

Comments

Sign in to join the discussion.

No comments yet — be the first to share your thoughts.